Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 824

1.

Micro-computed tomography (micro-CT) for intraoperative surgical margin assessment of breast cancer: A feasibility study in breast conserving surgery.

Qiu SQ, Dorrius MD, de Jongh SJ, Jansen L, de Vries J, Schröder CP, Zhang GJ, de Vries EGE, van der Vegt B, van Dam GM.

Eur J Surg Oncol. 2018 Jul 3. pii: S0748-7983(18)31166-1. doi: 10.1016/j.ejso.2018.06.022. [Epub ahead of print]

PMID:
30005963
2.

Molecular Imaging of Radiolabeled Bispecific T-cell Engager 89Zr-AMG211 Targeting CEA-positive Tumors.

Waaijer SJH, Warnders FJ, Stienen SK, Friedrich M, Sternjak A, Cheung HK, Terwisscha van Scheltinga AGT, Schröder CP, de Vries EG, Lub-de Hooge MN.

Clin Cancer Res. 2018 Jul 6. pii: clincanres.0786.2018. doi: 10.1158/1078-0432.CCR-18-0786. [Epub ahead of print]

PMID:
29980531
3.

Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database.

Moek KL, Fehrmann RSN, van der Vegt B, de Vries EGE, de Groot DJA.

Am J Pathol. 2018 Jun 21. pii: S0002-9440(18)30129-9. doi: 10.1016/j.ajpath.2018.05.014. [Epub ahead of print]

PMID:
29935166
4.

Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al.

Cherny NI, Dafni U, Piccart M, Latino NJ, Douillard JY, Bogaerts J, Karlis D, Zygoura P, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE.

Ann Oncol. 2018 May 1;29(5):1335-1338. doi: 10.1093/annonc/mdy108. No abstract available.

PMID:
29659680
5.

Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non-Ig scaffolds.

Warnders FJ, Lub-de Hooge MN, de Vries EGE, Kosterink JGW.

Med Res Rev. 2018 Apr 10. doi: 10.1002/med.21498. [Epub ahead of print] Review.

PMID:
29635825
6.

(18)F-fluoroestradiol Tumor Uptake is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.

Nienhuis HH, van Kruchten M, Elias SG, Glaudemans AWJM, de Vries EFJ, Bongaerts AHH, Schröder CP, de Vries EGE, Hospers GAP.

J Nucl Med. 2018 Mar 30. pii: jnumed.117.198846. doi: 10.2967/jnumed.117.198846. [Epub ahead of print]

PMID:
29602822
7.

Potential Red-Flag Identification of Colorectal Adenomas with Wide-Field Fluorescence Molecular Endoscopy.

Hartmans E, Tjalma JJJ, Linssen MD, Allende PBG, Koller M, Jorritsma-Smit A, Nery MESO, Elias SG, Karrenbeld A, de Vries EGE, Kleibeuker JH, van Dam GM, Robinson DJ, Ntziachristos V, Nagengast WB.

Theranostics. 2018 Feb 5;8(6):1458-1467. doi: 10.7150/thno.22033. eCollection 2018.

8.

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

J Natl Cancer Inst. 2018 Mar 12. doi: 10.1093/jnci/djy029. [Epub ahead of print] No abstract available.

PMID:
29546378
9.

Use of Video-consultation is Feasible During Follow-up Care of Patients with a Neuroendocrine Tumour.

Bouma G, de Hosson LD, van Essen H, de Vries EGE, de Groot DJA, Walenkamp AME.

Clin Oncol (R Coll Radiol). 2018 Jun;30(6):396. doi: 10.1016/j.clon.2018.02.027. Epub 2018 Mar 3. No abstract available.

PMID:
29506774
10.

Evolution in sentinel lymph node biopsy in breast cancer.

Qiu SQ, Zhang GJ, Jansen L, de Vries J, Schröder CP, de Vries EGE, van Dam GM.

Crit Rev Oncol Hematol. 2018 Mar;123:83-94. doi: 10.1016/j.critrevonc.2017.09.010. Epub 2017 Sep 20. Review.

PMID:
29482783
11.

Towards optimal personalized diet and vitamin supplementation in NET patients.

de Hosson LD, Stelwagen J, Bouma G, Sijtema B, Huitema S, van Faassen HJR, de Bock GH, de Groot DJA, Campmans-Kuijpers MJE, Kema IP, de Vries EGE, Walenkamp AME.

Endocr Relat Cancer. 2018 Mar;25(3):L23-L26. doi: 10.1530/ERC-17-0549. No abstract available.

PMID:
29431642
12.

Molecular Imaging in Cancer Drug Development.

Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, Lub-de Hooge MN, de Vries EGE.

J Nucl Med. 2018 May;59(5):726-732. doi: 10.2967/jnumed.116.188045. Epub 2018 Jan 25.

PMID:
29371402
13.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY.

Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review.

PMID:
29304358
14.

Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape.

Oosting SF, Fehrmann RS, de Vries EGE.

ESMO Open. 2017 Oct 9;2(4):e000272. doi: 10.1136/esmoopen-2017-000272. eCollection 2017. No abstract available.

15.

Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2018 Mar 1;29(3):774-775. doi: 10.1093/annonc/mdx747. No abstract available.

PMID:
29161364
16.

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart MJ, de Vries EGE, Latino NJ, Douillard JY, Cherny NI.

ESMO Open. 2017 Oct 9;2(4):e000216. doi: 10.1136/esmoopen-2017-000216. eCollection 2017.

17.

Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2018 Feb 1;29(2):521-522. doi: 10.1093/annonc/mdx649. No abstract available.

PMID:
29045537
18.

The antibody-drug conjugate target landscape across a broad range of tumour types.

Moek KL, de Groot DJA, de Vries EGE, Fehrmann RSN.

Ann Oncol. 2017 Dec 1;28(12):3083-3091. doi: 10.1093/annonc/mdx541.

PMID:
29045509
19.

ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE.

Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310.

PMID:
28945867
20.

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP.

J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14.

PMID:
28912144
21.

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.

Pool M, Kol A, de Jong S, de Vries EGE, Lub-de Hooge MN, Terwisscha van Scheltinga AGT.

MAbs. 2017 Nov/Dec;9(8):1370-1378. doi: 10.1080/19420862.2017.1371382. Epub 2017 Sep 5.

22.

Theranostics Using Antibodies and Antibody-Related Therapeutics.

Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, Lub-de Hooge MN, Brouwers AH, de Vries EGE.

J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. Review.

PMID:
28864618
23.

Immune Modulation Therapy and Imaging: Workshop Report.

Shields AF, Jacobs PM, Sznol M, Graham MM, Germain RN, Lum LG, Jaffee EM, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung DK, Wu AM, Sharon E, Shankar LK.

J Nucl Med. 2018 Mar;59(3):410-417. doi: 10.2967/jnumed.117.195610. Epub 2017 Aug 17.

PMID:
28818991
24.

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE.

Clin Cancer Res. 2017 Oct 15;23(20):6128-6137. doi: 10.1158/1078-0432.CCR-17-0311. Epub 2017 Jul 21.

25.

Web-Based Tailored Psychoeducation for Breast Cancer Patients at the Onset of the Survivorship Phase: A Multicenter Randomized Controlled Trial.

Admiraal JM, van der Velden AWG, Geerling JI, Burgerhof JGM, Bouma G, Walenkamp AME, de Vries EGE, Schröder CP, Reyners AKL.

J Pain Symptom Manage. 2017 Oct;54(4):466-475. doi: 10.1016/j.jpainsymman.2017.07.009. Epub 2017 Jul 13.

PMID:
28711750
26.

In Vivo Quantification of ERβ Expression by Pharmacokinetic Modeling: Studies with 18F-FHNP PET.

Antunes IF, Willemsen ATM, Sijbesma JWA, Boerema AS, van Waarde A, Glaudemans AWJM, Dierckx RAJO, de Vries EGE, Hospers GAP, de Vries EFJ.

J Nucl Med. 2017 Nov;58(11):1743-1748. doi: 10.2967/jnumed.117.192666. Epub 2017 Jul 13.

PMID:
28705918
27.

Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.

Pool M, de Boer HR, Hooge MNL, van Vugt MATM, de Vries EGE.

Theranostics. 2017 May 27;7(7):2111-2133. doi: 10.7150/thno.17934. eCollection 2017. Review.

28.

Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.

Pavel ME, Chen D, He W, Cushman S, Voi M, de Vries EGE, Baudin E, Yao JC.

Pancreas. 2017 Jul;46(6):751-757. doi: 10.1097/MPA.0000000000000830.

PMID:
28609362
29.

Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio.

Cherny NI, Dafni U, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski C, Piccart M, de Vries EGE.

Ann Oncol. 2017 Aug 1;28(8):2031-2032. doi: 10.1093/annonc/mdx200. No abstract available.

PMID:
28430861
30.

Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging.

Warnders FJ, Terwisscha van Scheltinga AGT, Knuehl C, van Roy M, de Vries EFJ, Kosterink JGW, de Vries EGE, Lub-de Hooge MN.

J Nucl Med. 2017 Aug;58(8):1210-1215. doi: 10.2967/jnumed.116.181586. Epub 2017 Mar 30.

PMID:
28360206
31.

89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.

Pool M, Terwisscha van Scheltinga AGT, Kol A, Giesen D, de Vries EGE, Lub-de Hooge MN.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1328-1336. doi: 10.1007/s00259-017-3672-x. Epub 2017 Mar 19.

32.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review.

33.

Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.

Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM.

Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9.

34.

89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma.

van Es SC, Brouwers AH, Mahesh SVK, Leliveld-Kors AM, de Jong IJ, Lub-de Hooge MN, de Vries EGE, Gietema JA, Oosting SF.

J Nucl Med. 2017 Jun;58(6):905-910. doi: 10.2967/jnumed.116.183475. Epub 2017 Jan 12.

35.

Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment.

van Beek AP, de Heide LJ, van Ginkel B, Slart RH, van der Horst-Schrivers AN, Boellaard R, de Vries EG, Noordzij W, Glaudemans AW.

Clin Nucl Med. 2017 Mar;42(3):163-168. doi: 10.1097/RLU.0000000000001496.

PMID:
28005639
36.

RECIST - learning from the past to build the future.

Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J.

Nat Rev Clin Oncol. 2017 Mar;14(3):187-192. doi: 10.1038/nrclinonc.2016.195. Epub 2016 Dec 20. Review.

PMID:
27995946
37.

Synthesis and Evaluation of the Estrogen Receptor β-Selective Radioligand 2-18F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with 16α-18F-Fluoro-17β-Estradiol.

Antunes IF, van Waarde A, Dierckx RA, de Vries EG, Hospers GA, de Vries EF.

J Nucl Med. 2017 Apr;58(4):554-559. doi: 10.2967/jnumed.116.180158. Epub 2016 Dec 1.

38.

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, Piccart MJ, Bogaerts J, Tabernero J, Latino NJ, de Vries EG.

ESMO Open. 2016 Oct 18;1(5):e000100. eCollection 2016. Review.

39.

Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.

Koch M, de Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams AL, Kranendonk ME, Terwisscha van Scheltinga AG, Aichler M, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WP, Van der Wall E, Garcia-Allende PB, van Diest PJ, de Vries EG, Walch A, van Dam GM, Ntziachristos V.

Cancer Res. 2017 Feb 1;77(3):623-631. doi: 10.1158/0008-5472.CAN-16-1773. Epub 2016 Nov 22.

40.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

41.

Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.

Cherny NI, Sullivan R, Dafni U, Bogaerts J, Kerst JM, Zielinski C, Piccart MJ, de Vries EG.

Ann Oncol. 2016 Nov;27(11):2136-2137. Epub 2016 Aug 29. No abstract available.

PMID:
27573563
42.

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, van Vugt MA, de Vries EG, Schröder CP, Fehrmann RS.

J Natl Cancer Inst. 2016 Oct 13;109(1). pii: djw192. Print 2017 Jan.

PMID:
27737921
43.

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Öberg K.

J Clin Oncol. 2016 Nov 10;34(32):3906-3913. doi: 10.1200/JCO.2016.68.0702. Epub 2016 Sep 30.

44.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart MJ.

Ann Oncol. 2017 Nov 1;28(11):2901-2905. doi: 10.1093/annonc/mdw258. No abstract available.

PMID:
27604385
45.

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.

Pool M, Kol A, Lub-de Hooge MN, Gerdes CA, de Jong S, de Vries EG, Terwisscha van Scheltinga AG.

Oncotarget. 2016 Oct 18;7(42):68111-68121. doi: 10.18632/oncotarget.11827.

46.

Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.

Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH.

JAMA Oncol. 2016 Aug 1;2(8):1030-7. doi: 10.1001/jamaoncol.2016.1726.

PMID:
27348762
47.

Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.

den Hollander MW, Westerink ND, Lubberts S, Bongaerts AH, Wolf RF, Altena R, Nuver J, Oosting SF, de Vries EG, Walenkamp AM, Meijer C, Gietema JA.

Oncologist. 2016 Aug;21(8):995-1001. doi: 10.1634/theoncologist.2015-0451. Epub 2016 Jun 21.

48.

A tribo-mechanical analysis of PVA-based building-blocks for implementation in a 2-layered skin model.

Morales Hurtado M, de Vries EG, Zeng X, van der Heide E.

J Mech Behav Biomed Mater. 2016 Sep;62:319-332. doi: 10.1016/j.jmbbm.2016.05.001. Epub 2016 May 10.

PMID:
27236420
49.

Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use.

Ter Weele EJ, Terwisscha van Scheltinga AG, Linssen MD, Nagengast WB, Lindner I, Jorritsma-Smit A, de Vries EG, Kosterink JG, Lub-de Hooge MN.

Eur J Pharm Biopharm. 2016 Jul;104:226-34. doi: 10.1016/j.ejpb.2016.05.008. Epub 2016 May 12.

PMID:
27179587
50.

89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.

Oosting SF, van Asselt SJ, Brouwers AH, Bongaerts AH, Steinberg JD, de Jong JR, Lub-de Hooge MN, van der Horst-Schrivers AN, Walenkamp AM, Hoving EW, Sluiter WJ, Zonnenberg BA, de Vries EG, Links TP.

J Nucl Med. 2016 Aug;57(8):1244-50. doi: 10.2967/jnumed.115.167643. Epub 2016 May 12.

Supplemental Content

Loading ...
Support Center